Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Export

@article{citeulike:2706027, abstract = {Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).}, address = {ICAR, Department of Nephrology, H\^{o}pital Piti\'{e}-Salp\^{e}tri\`{e}re, 83 boulevard de l'H\^{o}pital, 75013, Paris, France, vincent.launay-vacher@psl.aphp.fr.}, author = {Launay-Vacher, Vincent and Rey, Jean-Baptiste B. and Isnard-Bagnis, Corinne and Deray, Gilbert and Daouphars, Mikael}, citeulike-article-id = {2706027}, citeulike-linkout-0 = {http://dx.doi.org/10.1007/s00280-008-0711-0}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/18317762}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=18317762}, doi = {10.1007/s00280-008-0711-0}, issn = {0344-5704}, journal = {Cancer chemotherapy and pharmacology}, keywords = {cancer, insufficiency, oncology, renal}, month = {May}, number = {6}, pages = {903--909}, posted-at = {2008-07-03 08:13:46}, priority = {0}, title = {Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.}, url = {http://dx.doi.org/10.1007/s00280-008-0711-0}, volume = {61}, year = {2008} }

TY - JOUR ID - citeulike:2706027 L3 - citeulike-article-id:2706027 N2 - Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP). IS - 6 JF - Cancer chemotherapy and pharmacology SN - 0344-5704 AD - ICAR, Department of Nephrology, Hôpital Pitié-Salpêtrière, 83 boulevard de l’Hôpital, 75013, Paris, France, vincent.launay-vacher@psl.aphp.fr. EP - 909 TI - Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. VL - 61 SP - 903 KW - cancer KW - insufficiency KW - oncology KW - renal AU - Launay-Vacher, Vincent AU - Rey, Jean-Baptiste AU - Isnard-Bagnis, Corinne AU - Deray, Gilbert AU - Daouphars, Mikael PY - 2008/05// UR - http://dx.doi.org/10.1007/s00280-008-0711-0 ER -